Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:7 Issue:9 Number:13 ISSN#:2564-2537
ACE Report #10350
Ace Report Cover Cannabis

Efficacy of a cannabis-based oromucosal spray in managing peripheral neuropathic pain

How to Cite

OrthoEvidence. Efficacy of a cannabis-based oromucosal spray in managing peripheral neuropathic pain. ACE Report. 2018;7(9):13. Available from: https://myorthoevidence.com/AceReport/Report/10350

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment

Eur J Pain. 2014 Aug;18(7):999-1012. doi: 10.1002/j.1532-2149.2013.00445.x

Contributing Authors: M Serpell S Ratcliffe J Hovorka M Schofield L Taylor H Lauder E Ehler

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


303 patients with peripheral neuropathic pain (PNP) were randomized to either Nabiximols or placebo for 14 weeks. Significant improvements in pain, quality of sleep and Subject Global Impression of Change (SGIC) were found in patients that received Nabiximols compared to those that received placebo. No patients experienced severe treatment-related adverse events in the Sativex group versus one in ...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.